NEW YORK--(BUSINESS WIRE)--Spruce Point Capital Management, LLC (“Spruce Point” or “we” or “us”), a New York-based investment management firm that focuses on forensic research and short-selling, today ...
BofA Securities recently downgraded PROCEPT BioRobotics from Buy to Neutral, citing slowing utilization growth and moderating system sales for its Aquablation technology amid tighter hospital capital ...
Procept Biorobotics is a top performer in the medical device industry, offering relief for men with BPH. The company's minimally invasive procedure is experiencing rapid growth in both system sales ...
The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Truist Securities on December 18, 2025. The analyst firm set a price target for $47.00 expecting PRCT to rise to within 12 ...
Hosted on MSN
Oppenheimer Initiates Coverage of PROCEPT BioRobotics (PRCT) with Perform Recommendation
Fintel reports that on July 7, 2025, Oppenheimer initiated coverage of PROCEPT BioRobotics (NasdaqGM:PRCT) with a Perform recommendation. Analyst Price Forecast Suggests 40.25% Upside As of June 20, ...
In the latest quarter, 6 analysts provided ratings for PROCEPT BioRobotics (NASDAQ:PRCT), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...
Ratings for PROCEPT BioRobotics (NASDAQ:PRCT) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...
PROCEPT BioRobotics stands out in BPH therapy with its unique Aquablation technology and razor-and-blade business model, driving strong, recurring growth. PRCT's robust R&D investment, expanding ...
SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) just released its third-quarter report and things are looking bullish. It looks like a positive result overall, with revenues of US$83m beating forecasts ...
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good afternoon, and welcome to the PROCEPT BioRobotics Second Quarter 2025 Earnings Conference ...
REDWOOD SHORES, Calif.--(BUSINESS WIRE)--PROCEPT BioRobotics today announced that it has been selected as the winner of the “Best Healthcare Robotics Solution” award from MedTech Breakthrough, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results